

# CURRICULUM VITAE ANDREA DE CENSI, MD

## 1. General Information

Name  
Date and place of birth  
Marital status  
Nationality  
Working address

E-mail:

Home address

ORCID number

## 2. Education

1987 Specialization in Medical Oncology, Postgraduate Medical School, University of Genoa  
1983-4 Degree in Medicine and Surgery, Medical School, University of Pavia (first class honors)  
1977 School Leaving Certificate (Scientific Lyceum), S. Donato Milanese, Milan

## 3. Certifications and Qualifications

2013- 2019 National Scientific Qualification as University Full Professor issued by ANVUR (National Agency for the Evaluation of Universities and Research Institutes), an affiliate of ENQA (European Association for Quality Assurance in Higher Education).  
2014-2020 Honorary Professor, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry (renewal ongoing for 2021-25)  
2008-2013 European Society of Medical Oncology (ESMO), Board Certificate in Medical Oncology  
1984 National License for medical practice

#### 4. Conflict of Interest

I have not received any direct payment from pharmaceutical industry, including travels and lodging expenses, since December 31, 2014.

#### 5. Honors and Awards

July 28, 2010: *11<sup>th</sup> Annual advances in Cancer Prevention Lecture Award: "The future of cancer prevention clinical research", Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, USA*

August 18, 2011: *1<sup>st</sup> Karen Johnson Memorial Award Lecture on Breast Cancer Prevention at the National Cancer Institute, Bethesda, USA: "Metformin for cancer prevention. Review of the evidence and future perspectives."*

#### 6. Professional Employment (Clinical and Research Activities)

2018-	Scientific chair, regional department of oncology and hematology, Liguria Region
2014-2020	Honorary Professor, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry(renewal ongoing for 2021-25)
2004-Today	Director, Division of Medical Oncology, Ospedali Galliera, Genoa
2004-Today	Scientific Consultant, Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan
2001-2003	Director, Division of Chemoprevention, European Institute of Oncology, Milan
1998-2001	Director, Chemoprevention Unit, European Institute of Oncology, Milan
1995-1998	Assistant Director, Chemoprevention Unit, European Institute of Oncology, Milan
1994-1995	Deputy Chief, Department of Medical Oncology II National Institute for Cancer Research, Genoa
1993-1995	Consultant Oncologist at the Division of Urology, Nervi and Gallino Hospitals, ASL 3, Genoa
1988-1995	Consultant Oncologist at the University Department of Urology, San Martino General Hospital, Genoa
1988-1994	Tenured Assistant Oncologist at the Department of Medical Oncology II, National Institute for Cancer Research, Genoa
1985-1988	Fellow in Medical Oncology, University of Genoa, National Cancer Institute
1984-1985	Fellow in Medical Oncology, Fondazione Salvatore Maugeri, Pavia

## 7. Summary of Scientific and Clinical Activity

Dr. Andrea De Censi heads the Division of Medical Oncology at the Galliera Hospital, with 22 beds for Daily Hospital treatment and prolonged admission and 5 ambulatory rooms. His staff is formed by 6 medical oncologists, 9 nurses, 2 patient managers, 1 division's secretary, 6 research personnel including 1 bioengineer, 2 biologists, 2 study coordinators, 2 research nurses.

His main clinical activity is devoted to the treatment of patients with all kind of solid tumors, with special interest to cancers of the breast, colon, prostate, ovary, endometrium, lung and eye melanoma.

Dr. Andrea De Censi is a recognized international expert in cancer preventive therapy. Through his seminal work in breast cancer chemoprevention, he founded with Prof. Umberto Veronesi and Dr. Alberto Costa the first Clinical Unit of Cancer Chemoprevention in Italy at the European Institute of Oncology in 1995, since then mentoring many young clinicians and scientists to develop this growing branch of medical oncology. His second area of research is drug repurposing, such as for instance the use of aspirin and metformin in colon cancer and for obesity related cancers, or the use of hormone therapy for ovarian and endometrial cancers.

He is author of more than 230 publications in peer-reviewed Journals, mostly as first or senior author, with a H-index of 46 according to Scopus and a cumulative impact factor of approximately 2100.

He has been awarded as Principal Investigator of over 40 no-profit clinical trials sponsored by different National and International Agencies or Charities, including the US-National Cancer Institute, the European Commission, the Susan G Komen Foundation, The Italian Ministry of Health, the Italian Association for Cancer Research (AIRC), the Italian League against Cancer (LILT), the Umberto Veronesi Foundation, the Guido Berlucci Foundation and the Avon Foundation, with a total amount of funding to the Applicant Institution through competitive grants of more than 12 M €.

He has been holder of a Master Agreement with the US National Cancer Institute for the conduction of phase I and phase II clinical prevention trial for the years 2004-2008.

He is corresponding member of the American Association for Cancer Research and the American Society of Clinical Oncology.

### 7.1. Time/effort of weekly activity in percentage:

Clinical Care	50%
Research	30%
Teaching/Mentoring	10%
Administration	10%

## 8. Recent Invited Lectures (selected)

December 11, 2020	Virtual San Antonio Breast Cancer Symposium, Texas, Dec 11, Session Novel Strategies for Breast Cancer Prevention: Diet, Exercise and Vaccine Topic: Novel cancer prevention interventions
December 10, 2019	San Antonio Breast Cancer Conference 2019,” Educational Session - Breast Cancer Prevention Low dose tamoxifen and other approaches to improve chemoprevention uptake
November 3, 2019	European Gynecological Oncology Congress, oral presentation. Title: “(Anti-)Hormonal treatments and metformin for gynecologic cancer prevention and treatment.”
June 3, 2019	ASCO Chicago, Oral presentation “Effect modifiers in a randomized phase III trial of low-dose Tamoxifen in breast preinvasive disease
March 20, 2019	San Gallen 2019 Vienna Session Risk stratification and prevention in ductal in situ carcinoma. Oral presentation “Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS “

## 9. Teaching and Mentoring:

- Lecturer from 1988-1991 at the Postgraduate Medical School of Oncology in Genoa and since 1995 at the Continuing Medical Education Program of the European Institute of Oncology, Milan.
- Chair at the Master Course in Breast Cancer of the School of Medicine at the University of Milan in 2002 and 2003.
- Teaching lessons at the Postgraduate School of Medical Oncology, University of Genoa, years 2014-2016.
- Since 2009 he has supervised the monthly rotation of Genoa University Students in General Internal Medicine Specialty training at the Medical Oncology Division.
- Teaching lessons at *Oncoplastic And Reconstructive Surgery Of The Breast* Master, University of Genoa, Nov 20, 2017
- Teaching lessons at *Nursing in Clinical Research* Master, University of Genoa, Nov 28, 2018
- Teaching lessons at *Oncological Genetics* Master, University of Bergamo, Oct 11, 2019
- Teaching lesson at *Family and Community Nurses* Master, University of Genoa, Oct 23, 2020
- Teaching lessons at *Oncoplastic And Reconstructive Surgery Of The Breast* Master, University of Genoa, Jan 18,2021
- Teaching lessons at *Oncological Genetics* Master, University of Pavia, Jan 22, 2021
- Since 2004 he has trained in clinical research in oncology the following study coordinators:  
Daniela Branchi  
Domenico Marra

Sara Campora  
Davide Corradengo  
Marilena Petrera  
Eleonora Campazzi  
Silvia Caviglia  
Silvia Noonan  
Irene Maria Briata  
Alessia Cesario  
Tania Buttiron Webber  
Silvia Giuliano  
Riccardo Ranieri  
Laura Paleari  
Martina Nisi  
Marco Musso  
Martina Ugolini

He mentored the following young clinical researchers:

Dr. Virginia Livellara, 2016-2017  
Dr. Nicoletta Provinciali, medical oncologist, 2013-2016  
Dr. Carlotta Defferrari, medical oncologist, 2010-2014  
Dr. Mara Cafferata, medical oncologist, 2006-2009  
Dr. Alessandra Argusti geneticist 2004-2006  
Dr. Matteo Puntoni epidemiologist biostatistician 2005-2010  
Dr. Massimiliano Cazzaniga, MD, preventive oncologist, 1998-2003  
Dr. Davide Serrano, MD, medical oncologist, 2000-2002  
Dr. Harriet Johansson, PhD in endocrinology oncology, 1998-2003  
Dr. Fredrick Marriett, PhD in endocrinology oncology, 2000-2002  
Dr. Aliana Guerrieri-Gonzaga, PhD in preventive oncology, 1996 -1998.  
Dr. Clara Varricchio, MD, preventive oncologist, 2002-2003.  
Dr. Francesca Pigatto, medical geneticist, 2000-2003  
Dr. Alessandra Pallucca, medical oncologist, 2000-2001  
Dr. Stefania Rapisardi, medical oncologist, 2003  
Dr. Arianna Galli, genetic counselor, 2001-2003  
Dr. Silvia Diani, genetic counselor, 1998-2001  
Dr. Paolo Manetti, preventive oncologist, 1999-2000  
Dr. Gabriel Farante, preventive oncologist, 1998

#### **10. Research and Teaching Experience in Foreign Institutions**

- From Aug 30, 2015 to Sept 15, 2017. Honorary Professor at Institute of Preventive Medicine, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Chief Prof. Jack Cuzick.
- From Aug 20 to Sept 3, 2016. Honorary Professor at Institute of Preventive Medicine, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Chief Prof. Jack Cuzick.
- From August 17 to September 11, 2015. Honorary Professor at Institute of Preventive Medicine, Wolfson Institute of Preventive Medicine, Queen Mary University of London,.
- From August 1 to August 31, 2011. Visiting Professor at the Division of Cancer Prevention, Hosts: dr. Barry Kramer, dr. Leslie Ford, NCI, Bethesda

- From July 26 to 29, 2010. Visiting Professor at the Division of Cancer Prevention, Host: dr. Peter Greenwald, dr. Leslie Ford, NCI, Bethesda.
- From August 7 to 28, 2003. Visiting Professor at MSKCC, NY, Breast Surgery Unit, dr. Virgilio Sacchini; Medical Oncology, dr. Clifford Hudis.
- From June 21 to July 5, 2001. Visiting Professor at MSKCC, NY, Breast Surgery Unit, Host: dr. Virgilio Sacchini; Medical Oncology, dr. Clifford Hudis.
- From July 15 to August 30, 1999. Visiting Professor at Memorial Sloan-Kettering Cancer Center, New York. Clinical Genetics Service, Hosts: Dr. Kenneth Offit, dr. Mark E Robson, Breast Surgery Unit, Host: dr. Patrick Borgen; Division of Medical Oncology, Host: dr. Larry Norton.

## 11. Extramural responsibilities

2019-2022	Member of Technical and Scientific Committee- Italian Association for Cancer Research, AIRC Fellowship
2014-2020	Honorary Professor, Queen Mary University of London within the Wolfson Institute of Preventive Medicine and the Barts & The London School of Medicine and Dentistry: Collaboration with Prof. Jack Cuzick and his team to conduct clinical trials in the adjuvant treatment of breast cancer and the preventive therapy of different cancers. Writing grant applications and papers.
2004-2020	Scientific advisor, Scientific Consultant, Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan: strategic planning, design and overview of clinical trials; data analysis and publications.
2015-18	Expert member nominated by AIFA of the Superior Health Council sub committee on “Genomics in public health”.
2015-	Steering Committee Member for Breast cancer Guidelines of the Italian Association of medical Oncology (AIOM)
2017 -2018	Leading Investigator of the National Survey on Conflict of Interest (COI) among Italian Medical Oncologists sponsored by CIPOMO
2018-	<ul style="list-style-type: none"> <li>• Member of the AACR Cancer Prevention, Early Detection, and Interception Research Grants Scientific Review Committee</li> <li>• Experimental Cancer Medicine Centres (ECMC) Network, UK</li> <li>• Public Health Genomics, established by the National Superior Council of the Italian Ministry of Health</li> <li>• WP 5 Writing Group “Public Health Genomics in Cancer” -EU Joint Action on Cancer Control.</li> <li>• HTA committee on Lynch syndrome supported by Vihtali, a spin-off of Catholic University, Rome, Italy</li> <li>• Liguria oncology network, Recommendations on the use of novel antitumor drugs</li> <li>• AACR International Conference Committee on the annual meeting of Frontiers in Cancer Prevention Research, 2011-12</li> </ul>

- ASCO Prevention Committee 2010-12
- Cancer Prevention Committee of the European Society of Medical Oncology, 2008-2012
- National Oncology Commission from 2000 to 2001
- Scientific Committee of the Italian League against Cancer in Rome 2000-2010
- National Prostate Cancer Project PONCAP 1985-1991

## **12. Reviewer and editorial activity:**

### **12.1 Journals**

Annals of Oncology

Breast Cancer Research and Treatment British Medical Journal

Cancer Epidemiology Biomarkers and Prevention Cancer Research

Clinical Cancer Research

Clinical Reviews in Oncology/Hematology European Journal of Cancer

International Journal of Cancer Jama

Journal of Clinical Oncology

Journal of National Cancer Institute Lancet

Nature Clinical Practice Oncology Science Translational Medicine

### **12.2 Journal Editorial Boards:**

Journal of Clinical Oncology, 2005 to 2007.

Cancer Prevention Research (CaPR), 2014-.

### **12.3 Study sections (expert reviewer) for Research Organizations:**

Cancer Research UK

Italian League for Cancer Research (AIRC)

European Organization for Research and Treatment of Cancer (EORTC)

Dutch Cancer Research

Slovenian Research Agency European Commission

Swiss Cancer League

## **13. Social commitments**

- National Testimonial for the Italian Association for Cancer Research (AIRC) Orange Campaign 2017.

Numerous public debates and interviews on cancer prevention sponsored by AIRC.

## **14. Research Projects as Principal Investigator obtained after a competitive application and external peer review**

### **1. Bando: RICERCA FINALIZZATA 2019**

titolo: meTfoRmin, nIghtly fAstiNg and low-GLyemic index food diEt in breast cancer: a randomized,

window of opportunity pre-surgical trial. TRIANGLE Trial.  
Codice: RF-2019-12370733 Total amount:: 450.000€

2. Bando: RFA-CA-19-031 Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required) – National Institutes of Health (NIH)  
titolo: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.  
Codice: UG1CA242609 , Total amount: 941.526 \$
3. Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy . (Call for Proposals 2018) Project Coordinator Andrea DeCensi, E.O. Ospedali Galliera, Genova-Italy DeCensi P.I., 2018-2019;  
"Letrozole for Estrogen/Progesterone Receptor positive low-grade Epithelial ovarian cancer. A randomized phase III trial"  
Total amount: 1.032.000,00 €
4. Sponsor: Compagnia di San Paolo (Call for Proposals 2017) , Andrea De Censi PI GOMOB (Galliera Oncology Mobile) Development and pilot study of a handy smartphone tool for remote recording of toxicities from cancer treatment. Total amount: 166.000 €
5. Sponsor: Ricerca Finalizzata 2017, Italian Ministry of Health, Roma-Italy Andrea DeCensi PI "EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. RF-2016-02364623"  
Total Amount: 434.025,00 €
6. Sponsor: Italian Medicine Agency (AIFA) Call 2017, Andrea DeCensi PI;  
"EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. AIFA-201602364326"  
Total Amount: 1.101.108,00 €
7. Sponsor: National Institute of Health, National Cancer Institute, Andrea DeCensi Co-PI;  
"Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial" MDA2014-04-01  
Total Amount:112.000€
8. Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy . (Call for Proposals 2014) Project Coordinator Andrea DeCensi, E.O. Ospedali Galliera, Genova-Italy DeCensi P.I., 2014-2017;  
"A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal advanced adenoma or cancer."  
Total amount: 332.000€
9. Sponsor: European Research Area (ERA)-NET on Translational Cancer Research (TRANSCAN) (JTC 2013)  
Project Coordinator Andrea DeCensi, E.O.Ospedali Galliera, Genova-Italy. DeCensi P.I., 2014-2017;  
"A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients." CANCER13-FP-056  
Total amount: 1.342.550€
10. Sponsor: Umberto Veronesi Foundation (FUV) Milano-Italy;  
"Randomized window of opportunity trial of anthocyanins and curcumin versus placebo in



subjects with colorectal adenoma. The MIRACOL Study”.

Total amount: 230.000€

- 11.** Sponsor: Ricerca Finalizzata 2009, Italian Ministry of Health, Roma-Italy, A, DeCensi (PI-Operative Unit), 2009-2011  
A Pre-Surgical Phase II Study On Activity Of Metformin On Breast Cancer Cells Proliferation.  
RF2009- 1532226  
Total amount: 27.777,00 €
- 12.** Sponsor: Programma Tevere, Italian Ministry of Health, Roma-Italy;  
Phase III study of low dose tamoxifen in women with breast intraepithelial neoplasia.  
Total amount: 521.143,88 €
- 13.** Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy DeCensi (PI) Call 2008.  
Response biomarkers of tamoxifen at low dose for breast intraepithelial neoplasia. A clinical study.  
Total amount: 200.000€
- 14.** Sponsor: Italian League against Cancer (LILT), Roma-Italy DeCensi (PI), 2008-2012  
“CYP2D6 genotype and tamoxifen response in women with breast intraepithelial neoplasia”  
Total amount: 50.030,00 €
- 15.** Sponsor: Berlucci Foundation, Brescia-Italy; DeCensi (PI), 2008. Prevention of prostate cancer with a weekly administration of bicalutamide in subjects with elevated PSA and negative biopsy. The WEB study  
Total amount: 290.000 €
- 16.** Sponsor: Italian League against Cancer (LILT), Call 2008, Roma-Italy.  
Phase I study of weekly bicalutamide in men with negative biopsy and high PSA Pre-web. A.  
De Censi PI.  
Total amount: to be retrieved
- 17.** Sponsor: European Institute of Oncology Milan-Italy, DeCensi(PI), 2006-2011  
A phase II study of gw572016 (Lapatinib TM) on cell proliferation in her-2/neu (erbb2) positive breast cancer before surgery.  
Total amount: 85.000 €
- 18.** Sponsor: Regional Agency of Liguria, Genova-Italy; Italian League against Cancer (LILT), Roma-Italy; Carige Fondation, Genova-Italy  
DeCensi (PI), 2006  
Phase I/II study of Allopurinol in Subjects with colorectal adenoma before polypectomy.  
Total amount: 112.750 €
- 19.** Sponsor: International Breast Cancer Study Group (IBCSG) Bern-Switzerland  
DeCensi (PI), 2005-2008  
Investigating Bone Density and Bone Loss without Baseline Information” BIG1-98.Bone substudy.  
Total amount: 96.400,00 €
- 20.** Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy DeCensi (PI), 2005  
Second primary tumors: markers, etiology and predisposing factors.  
Total amount: 120.000 €

21. Sponsor: Italian League against Cancer (LILT), Roma-Italy;  
Total amount: to be retrieved
  
22. Sponsor: Association for Cancer Research (AIRC), Milano-Italy; DeCensi (PI), 2004  
A Biomarker phase II Trial Of Intermittent, Low Dose Bicalutamide In Subjects At High Risk For Prostate Cancer (Pre-Web Study)  
Total amount: 270.000 €
  
23. Sponsor: Italian association for Cancer Research (AIRC), Milano-Italy;
  
24. Sponsor: Italian League against Cancer (LILT), Roma-Italy  
DeCensi (PI), 2004  
Randomized window of opportunity trial of finasteride or low dose bicalutamide or placebo in men with prostate cancer before radical prostatectomy.  
Total amount: 260.000 €
  
25. Sponsor: Italian Ministry of Health, Roma-Italy  
DeCensi (PI), 2002-2004  
Preclinical and clinical activity of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, in ER negative breast cancers  
Total amount: 250.000,00 €
  
26. Sponsor: Italian League against Cancer (LILT), Roma-Italy DeCensi (PI), 2002-2003  
Identification of cellular atypia by ductal lavage in patients at increased risk for breast cancer  
Total amount: 145.000,00 €
  
27. Sponsor: Avon Foundation, New York DeCensi (PI), 2002  
Cellular atypia and KI-67 in ductal lavage as risk biomarkers in patients at increased risk for breast cancer.  
Total amount: 100.000 \$
  
28. Sponsor: Italian League against Cancer (LILT), Roma-Italy;  
The HOT study  
Total amount: to be retrieved
  
29. Sponsor: Italian Foundation for Cancer Research (FIRC), Milano-Italy  
DeCensi (PI), 2001-2003  
A Phase III Study of Hormone replacement therapy opposed by low dose tamoxifen: the HOT Study.  
Total amount: 540.000,00 €
  
30. Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy DeCensi (PI), 2001-2003  
Phase III trial of nimesulide for prevention of colorectal adenoma recurrence.  
Total amount: 196.120,00 €
  
31. Sponsor: Susan G. Komen Breast Cancer Foundation, Dallas TX DeCensi (PI), 2000-2002  
A biomarker trial of tamoxifen at low doses in HRT users  
Total amount: 249.672 \$
  
32. Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy  
DeCensi (PI), 1998-2001  
Modulation of ovarian cancer cell proliferation and apoptosis by fenretinide (4-HPR) in patients

with ascites. A Phase I-II window of opportunity trial.

Total amount: L.210.000.000

33. Sponsor: Susan G. Komen Breast Cancer Foundation Dallas, TX DeCensi (PI), 1998-2000  
Potential benefit of fenretinide, a vitamin A analog on HRT-induced breast cancer risk”  
Total amount: 178.450,00 \$
34. Sponsor: National Institute of Health, National Cancer Institute(grant # CA 77188-01),  
Bethesda, MD DeCensi (PI), 1997-2002  
Phase IIb biomarker trial of low dose tamoxifen and 4-HPR in early breast cancer.  
Total amount: 1.303.460,00 \$
35. Sponsor: National Institute of Health, National Cancer Institute (grant # CA 72286-02),  
Bethesda, MD DeCensi (CO-PI), 1997-2001  
IGF-I modulation by 4-HPR and breast cancer risk  
Total amount: 630.750,00 \$
36. Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy;  
Effect of fenretinide, a synthetic retinoid, on DNA flow cytometry  
Total amount: Lit 95.000.000
37. Sponsor: National Institute of Health, National Cancer Institute (grant # CA-56457), Bethesda,  
MD  
DeCensi (PI ), 1995-1997  
Modulation of DNA content flow cytometry by Fenretinide in superficial bladder tumors.  
Grants: 293.000 \$
38. Sponsor: Association for Cancer Research (AIRC), Milano-Italy, DeCensi (Co-PI), 1995-1997.  
Chemoprevention of breast cancer: tamoxifen, fenretinide and estrogen replacement therapy  
Total amount: Lit 300.000.000
39. Sponsor: Association for Cancer Research (AIRC), Milano-Italy  
DeCensi (PI), 1992-1994  
Biological profile and toxicity of fenretinide in superficial bladder cancer  
Total amount: Lit 120.000.000

#### **15. Research Projects as local Principal Investigator obtained after competitive public call and external peer review**

1. International Breast Cancer Study Group (IBCSG) Bern-Switzerland. DeCensi (PI), 2010- on going follow-up
  - A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer (SOLE Study - BIG 1-07).  
Amount: 1500 € per patientPatients enrolled: 13
2. University of Pennsylvania Medical Center, USA  
DeCensi (PI for Italy), 2003-2005
  - MRI and mammographic density as biological markers of breast cancer and tamoxifen response.  
Total amount: (NIH grant # 1P01CA82707-01A1) 400.000\$

3. Cancer Research UK, London DeCensi (PI for Italy), 2003-2008
  - Prevention of breast cancer with anastrozole. The IBIS II study. Total amount: UK 1.500 € per subject
4. Italian Ministry of Health, Roma-Italy DeCensi (PI- Operative Unit), 2002-2004
  - Endocrine-metabolic modulators of penetrance of familial cancer Total amount: 168.000,00 €
5. INT Milano  
DeCensi (PI- Operative Unit), 2006-2007
  - Demetra: a Retrospective Observational Study in Women with Her2 Metastatic Cancer treated with Trastuzumab.  
Patients enrolled:38
6. AIFA (Agenzia Italiana del Farmaco) Italy  
DeCensi (PI- Operative Unit) 2008-on-going
  - TAILOR (TArceva Italian Lung Optimization tRial) – Optimization of erlotinib for the treatment of patients with advanced non-smal cell lung cancer: an itaian randomized trial”.  
Patients enrolled:4
7. ISS (Istituto Superiore di Sanità) Italy DeCensi (PI- Operative Unit) 2008-on-going
  - Diagnostic surveillance on women with genetic risk breast cancer.  
Patient enrolled: 10
8. University of Modena and Reggio Emilia,Italy  
DeCensi (PI- Operative Unit) 2010-on going  
With the Support of AIFA (Agenzia Italiana del Farmaco) Italy
  - Short-her: multicentric randomized phase III trial of 2 different adjuvant chemotherapy regimens plus 3 vs 12 months of trastuzumab in her2 positive breast cancer patients.  
Patients enrolled:4
9. IRST Meldola – Dr. Dino Amadori - With the Support of Italian Health Ministry  
DeCensi (PI- Operative Unit) 2011-on going
  - Androgen Receptors as targets for the treatment of estrogen and progesterin positive and negative breast cancer.Patients enrolled: center activation is on going  
Grant: 15.000€
10. National Cancer Institute, Naples, Italy  
DeCensi (PI- Operative Unit) 2012- on going Follow-up
  - A multicenter study in Patients with stage III-IV epithelial ovarian cancer trated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors. (MITO-16 - MANGO-OV2)Patients enrolled: 9  
Grant: 1.500
11. National Cancer Institute, Naples, Italy
  - DeCensi (PI- Operative Unit) 2014 –on goingA multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line. (MITO-16b - MANGO-OV2b – ENGOT-ov 17)  
Patients enrolled: 3
12. Mario Negri Gynecologic Oncology Group – MaNGO

DeCensi (PI- Operative Unit) 2014-on going

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Patients enrolled: 10

Grant: 1.000

13. MD Anderson Cancer Center NCI sponsored trial – Istituto Europeo Oncologico (IEO)  
2018-2019 Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial  
Patients enrolled so far:18  
Grant: 90.000€

## 16. Publication Statistics

ORCID number 0000000326354491

### Total papers: 250:

- 238 retrieved on PubMed; (DeCensi A[Author] OR DeCensi A[Investigator]) OR (De Censi A[Author] OR De Censi A[Investigator])
- 12 retrieved from other sources

### Cumulative Impact Factor:

1.378.816,7

(calculated by JCR)

H-index: 49 (calculated by Scopus)

### PubMed search

N	Authors	Title	Publication and PMID	IF
238	Gennari A, Foca F, Zamarchi R, Rocca A, Amadori D, <b>De Censi A</b> , Bologna A, Cavanna L, Gianni L, Scaltriti L, Rossi E, Facchinetti A, Martini V, Bruzzi P, Nanni O.	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.	Breast Cancer Res Treat. 2020 May;181(1):61-68. doi: 10.1007/s10549-020-05596-4. Epub 2020 Mar 21. PMID: 32200486	3.831
237	Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E,	Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly	Cancer. 2020 Aug 4. doi: 10.1002/cncr.33120. Epub ahead of print. PMID: 32749681	5742

	Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G.	patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group.		
236	Johansson H, Aristarco V, Gandini S, Gjerde J, Macis D, Guerrieri-Gonzaga A, Serrano D, Lazzeroni M, Rajasekaran A, Williard CV, Mellgren G, <b>DeCensi A</b> , Bonanni B	Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.	Pharmacogenomics J. 2020 Feb;20(1):19-26. doi: 10.1038/s41397-019-0087-z. Epub • 2019 Apr. PMID: 30967597	2.910
235	Lazzeroni M, <b>DeCensi A</b> , Guerrieri-Gonzaga A, Pagan E, Bagnardi V, Macis D, Serrano D, Vingiani A, Bonizzi G, Barberis M, Pruneri G, Wagner S, Gandini S, Viale G, Bonanni B.	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.	Mod Pathol. 2020 • Jun;33(6):1065-1077. doi: 10.1038/s41379-020-0452-0. Epub 2020 Jan 10. PMID: 31925342	5.988
234	Lazzeroni M, DeCensi A.	De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.	• J Clin Oncol. 2020 Mar 3;JCO2000124. doi: 10.1200/JCO.20.00124 PMID: 32125939	32.956
233	Palazzolo G, Mollica H, Lusi V, Rutigliani M, Di Francesco M, Pereira RC, Filauro M, Paleari L, DeCensi A, Decuzzi P.	Modulating the Distant Spreading of Patient-Derived Colorectal Cancer Cells via Aspirin and Metformin.	Transl Oncol. 2020 Apr;13(4):100760. doi: 10.1016/j.tranon.2020.100760. Epub 2020 Apr 1. PMID: 32247264	3.558
232	Pastorino R, Basile M, Tognetto A, Di Marco M, Grossi A, Lucci-Cordisco E, Scaldaferri F, <b>De Censi A</b> , Federici A, Villari P, Genuardi M, Ricciardi W, Boccia S.	Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.	PLoS One. 2020 Jul 1;15(7):e0235038. doi: 10.1371/journal.pone.0235038 PMID: 32609729	2.740
231	Paleari L, Rutigliani M, Siri G, Provinciali N, Colombo N, <b>Decensi A</b> .	Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma:	Int J Mol Sci. 2020 Mar 23;21(6):2227. doi: 10.3390/ijms21062227 PMID: 32210157	4.556

		A Retrospective Cohort Study.		
230	Visvanathan K , Fabian CJ , Bantug E , Brewster AM , Davidson NE , DeCensi A, Floyd JD , Garber JE , Hofstatter EW , Khan SA , Katapodi MC , Pruthi S , Raab R , Runowicz CD , Somerfield MR	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.	<ul style="list-style-type: none"> <li>J Clin Oncol. 2019 Sep 3;JCO1901472. doi: 10.1200/JCO.19.01472 PMID: 31479306</li> </ul>	32.956
229	Elgendy M, Cirò M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, Cazzoli R, Curigliano G, DeCensi A, Bonanni B, Budillon A, Pelicci PG, Janssens V, Ogris M, Baccarini M, Lanfrancone L, Weckwerth W, Foiani M, Minucci S.	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 $\beta$ -MCL-1 Axis.	<p>Cancer Cell. 2019 May 13;35(5):798-815.e5. doi: 10.1016/j.ccell.2019.03.007. Epub</p> <ul style="list-style-type: none"> <li>2019 Apr 25. PMID: 31031016</li> </ul>	23916
228	DeCensi A, Puntoni M, Guerrieri Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Marcella Gulisano, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Webber Buttiron T, Boni L and Bernardo Bonanni	Randomized placebo controlled trial of low dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia	<p>J Clin Oncol. 2019 Apr 11;JCO1801779. doi: 10.1200/JCO.18.01779. [Epub ahead of print] PubMed PMID: 30973790.</p>	28.349
227	Johansson H, Aristarco V, Gandini S, Gjerde J, Macis D, Guerrieri-Gonzaga A, Serrano D, Lazzeroni M, Rajasekaran A, Williard CV, Mellgren G, DeCensi A, Bonanni B.	Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.	<p>Pharmacogenomics J. 2019 Apr 10. doi: 10.1038/s41397-019-0087-z. [Epub ahead of print] PubMed PMID: 30967597.</p>	3.503

226	Rossi UG, Rutigliani M, DeCensi A.	Hepatobiliary and Pancreatic: Sub-Glisson's capsule hepatic multiple nodular formations.	J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1111/jgh.14618. [Epub ahead of print] Review. PubMed PMID: 30834597.	3.632
225	Greppi M, Tabellini G, Patrizi O, Candiani S, Decensi A, Parolini S, Sivori S, Pesce S, Paleari L, Marcenaro E.	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.	Int J Mol Sci. 2019 Feb 19;20(4). pii: E890. doi: 10.3390/ijms20040890. Review. PubMed PMID: 30791364; PubMed Central PMCID: PMC6412350.	4.183
224	Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.	N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. PubMed PMID: 30786186.	70.670
223	DeCensi A, Gescher A.	An Abstract Provides "seAFood" for Thought.	Cancer Prev Res (Phila). 2019 Mar;12(3):123-124. doi: 10.1158/1940-6207.CAPR-19-0033. Epub 2019 Jan 30. PubMed PMID: 30700438.	3.866
222	Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A; MYME investigators.	Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.	Breast Cancer Res Treat. 2018 Dec 7. doi: 10.1007/s10549-018-05070-2. [Epub ahead of print] PMID: 30536182.	3.471



221	Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A.	The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.	BMC Cancer. 2018 Dec 4;18(1):1210. PMID: 30514262	3.288
220	Serrano D, Gandini S, Guerrieri-Gonzaga A, Feroce I, Johansson H, Macis D, Aristarco V, Bonanni B, DeCensi A.	A. Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women	Cancer Prev Res (Phila). 2018 Oct 23. pii: canprevres.0073.2018. doi: 10.1158/1940-6207.CAPR-18-0073. [Epub ahead of print] PubMed PMID: 30352838.	4021
219	Mollica H, Coclite A, Miali ME, Pereira RC, Paleari L, Manneschi C, DeCensi A, Decuzzi P.	Deciphering the relative contribution of vascular inflammation and blood rheology in metastatic spreading.	Biomicrofluidics. 2018 May 17;12(4):042205. doi: 10.1063/1.5022879. eCollection 2018 Jul. PubMed PMID: 29861816	2.571
218	Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L.	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).	Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7. Review. PMID: 29886394.	7.191
217	De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G	Italian Nivolumab Renal Cell Cancer Early Access Program Group. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.	BJU Int. 2018 Jun 29. doi: 10.1111/bju.14461. [Epub ahead of print] PMID: 29956884	4.688
216	DeCensi A, Numico G, Ballatori E, Artioli F, Clerico M, Fioretto L, Livellara V, Ruggeri B, Tomirotti M, Verusio C, Roila F, Italian College of Chief Medical	Conflict of interest among Italian medical oncologists: a national survey.	BMJ Open. 2018 Jun 30;8(6):e020912. doi: 10.1136/bmjopen-2017-020912. PMID: 29961019	23.259

	Oncologists (CIPOMO).			
215	Patrone S, Maric I, Rutigliani M, Lanza F, Puntoni M, Banelli B, Rancati S, Angelini G, Amaro A, Ligorio P, Defferrari C, Castagnetta M, Bandelloni R, Mosci C, DeCensi A, Romani M, Pfeffer U, Viaggi S, Coviello DA.	Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.	Genes Chromosomes Cancer. 2018 Apr 24. doi: 10.1002/gcc.22541. [Epub ahead of print] PubMed PMID: 29689622.	3.362
214	Paleari L, Burhenne J, Weiss J, Foersch S, Roth W, Parodi A, Gnant M, Bachleitner-Hofmann T, Scherer D, Ulrich CM, Stabuc B, Puntoni M, Coccia G, Petrera M, Haefeli WE, DeCensi A.	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome.	Gastroenterology. 2018 Apr;154(5):1543-1545. doi: 10.1053/j.gastro.2017.12.040. Epub 2018 Mar 8. PubMed PMID: 29526732.	20.773
213	Paleari L, DeCensi A.	Endocrine therapy in ovarian cancer: where do we stand?	Curr Opin Obstet Gynecol 2018 Feb;30(1):17-22. doi: 10.1097/GCO.0000000000000423. PubMed PMID: 29176513.	2.821
212	Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.	Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. PubMed PMID: 27951450.	7191
211	Noonan S, Pasa A, Fontana V, Caviglia S, Bonanni B, Costa A, Smith SG, Peccatori F, DeCensi A.	A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene.	Cancer Prev Res (Phila). 2017 Oct 23. pii: canprevres.0162.2017. doi: 10.1158/1940-6207.CAPR-17-0162. [Epub ahead of print] PMID:29061559	3.985
210	Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L, Zanardi S, DeCensi A, Ferrarazzo G, Gambaro M, Grillo	(64)CuCl(2) PET/CT in prostate cancer relapse.	J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628. [Epub ahead of print] PMID:28887398	6.646

	Ruggieri F, Campodonico F, Tomasello L, Timossi L, Sola S, Lopci E, Cabria M.			
209	Heckman-Stoddard BM, DeCensi A, Sahasrabudde VV, Ford LG	Repurposing metformin for the prevention of cancer and cancer recurrence.	Diabetologia. 2017 Aug 3. doi: 10.1007/s00125-017-4372-6. [Epub ahead of print] Review. PMID: 28776080	6.080
208	Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi	Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis	Gynecol Oncol. 2017 Jul 10. pii:S0090-8258(17)30977-0. doi:10.1016/j.ygyno.2017.06.036. [Epub ahead of print] PMID:28705409	4.959
207	Rondanina G, Puntoni M, Guerrieri-Gonzaga A, Marra D, Bonanni B, DeCensi A.	Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users.	Breast. 2017 Aug;34:108-114. PMID:28570956	2.801
206	Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrada S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G.	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.	Ann Oncol. 2017 Feb 1;28(2):321-328. PMID: 28426105	11.855
205	Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.	A presurgical study of lecithin formulation of green tea extract in women with early breast cancer.	Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. PMID: 28400479	3.985
204	Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni	Adjuvant therapy in patients with ductal carcinoma in situ of the	Cancer Treat Rev. 2017 Apr;55:1-9. PMID: 28262606	8.589

	B, DeCensi A.	breast: The Pandora's box.		
203	Smith SG, Foy R, McGowan JA, Kobayashi LC, de Censi A, Brown K, Side L, Cuzick J.	Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.	Br J Gen Pract. 2017 Jun;67(659):e414-e427. PMID: 28193617	3041
202	Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.	Eur J Cancer. 2017 Jan;71:34- 42. PMID: 27951450	6.029
201	Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petretera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A.	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.	Transl Oncol. 2016 Dec;9(6):600-605. PMID:27916295	3.077
200	Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González- Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N.	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.	Int J Gynecol Cancer. 2017 Jan;27(1):50-58. PMID: 27749456	2.369

199	Provinciali N, Suen C, Dunn BK, DeCensi A.	Raloxifene hydrochloride for breastcancer risk reduction in postmenopausal women.	Expert Rev Clin Pharmacol. 2016 Sep 12:1-10. PMID: 27583816	2.488
198	Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.	A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.	Breast Cancer Res Treat. 2016 Aug;159(1):97-108. PMID: 27484880	4085
197	Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.	Int J Cancer. 2016 Nov 1;139(9):2127-34. PMID:27381855	5531
196	Albini A, DeCensi A, Cavalli F, Costa A.	Cancer Prevention and Interception: A New Era for Chemopreventive Approaches.	Clin Cancer Res. 2016 Sep 1;22(17):4322-7. PMID: 27220959	8738
195	Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'amico M, DeCensi A.	Dual block with lapatinib and trastuzumab versus single agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials.	Clin Cancer Res. 2016 Sep 15;22(18):4594-603. PMID: 27140927	8738
194	Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.	Prognostic significance of VEGF after twenty year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer.	Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. PMID: 27045034.	3.887
193	Fujiwara K, Monk BJ,	Health-related Quality of	Ann Oncol.	9269

	Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F.	Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).	2016 Jun;27(6):1006-13. PMID: 27029706	
192	Capitanio S, Bongioanni F, Piccardo A, Campus C, Gonella R, Tixi L, Naseri M, Pennone M, Altrinetti V, Buschiazzo A, Bossert I, Fiz F, Bruno A, DeCensi A, Sambuceti G, Morbelli S.	Comparisons between glucose analogue 2-deoxy-2-((18F)fluoro-D-glucose and (18F)-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.	World J Radiol. 2016 Feb 28;8(2):200-9. PMID: 26981229	N/A
191	Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensch N, DeCensi A, Gandini S.	Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.,	Int J Cancer. 2016 Jul 1;139(1):212-9. doi: 10.1002/ijc.30062. Epub 2016 Mar 12. PMID: 26916107	5531
190	Lazzeroni M, DeCensi A.	Alternate dosing schedules for cancer chemopreventive agents	Semin Oncol. 2016 Feb;43(1):116-22. PMID: 26970130	3954
189	Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.	Repurposing old drugs to chemoprevention: the case of metformin.	Semin Oncol. 2016 Feb;43(1):123-33 PMID: 26970131	3954
188	Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, De Censi A, Bonanni B	A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients.	Cancer Prev Res (Phila). 2016 May;9(5):349-56. PMID: 26928670	3.887
187	Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D,	A Presurgical Study of Oral Silybin-	Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. PMID: 26526990	3.887

	Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.	Phosphatidylcholine in Patients with Early Breast Cancer.		
186	DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J.	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.	Ecancermedalscience. 2015 Nov 24;9:595. PMID: 26635899	N/A
185	Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.	PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.	Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26. PMID: 26712086	3.212
184	Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.	Metformin: risk-benefit profile with a focus on cancer.	Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. PMID: 26359221	2911
183	De Censi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.	Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial	Cancer Prev Res (Phila). 2015 Oct;8(10):888-94. PMID: 26276754	4444
182	Bruno S, Ledda B, Tenca C, Ravera S, Orenco AM, Mazzarello AN, Pesenti E, Casciaro S, Racchi O, Ghiotto F, Marini C, Sambuceti G, DeCensi A, Fais F.	Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.	Oncotarget. 2015 Sep 8;6(26):22624-40. PMID: 26265439	6359
181	Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G, DeCensi A.	<sup>18</sup> F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with <sup>18</sup> F-NaF PET/CT.	Nuklearmedizin. 2015;54(4):163-72. PMID:26165806	1.494
180	Paparo F, Piccardo A,	Multimodality fusion	Abdom Imaging. 2015	1.630

	Bacigalupo L, Piccazzo R, Rollandi L, Galletto Pregliasco A, Filauro M, DeCensi A, Rollandi GA.	imaging in abdominal and pelvic malignancies: current applications and future perspectives.	Oct;40(7):2723-37. PMID: 25952574	
179	Gennari A, Costa M, Puntoni M, Paleari L, De Censi A, Sormani MP, Provinciali N, Bruzzi P.	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.	Breast Cancer Res Treat. 2015 Apr;150(2):405-13. PMID: 25744295	3.940
178	Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B.	Long-term effects of inhaled budesonide on screening-detected lung nodules.	Ann Oncol. 2015 May;26(5):1025-30. PMID: 25672894	7040
177	Principi M, De Censi A.	Prevention of colorectal adenomas.	Colorectal Dis. 2015 Jan;17 Suppl 1:20-4. PMID:25511857	2.452
176	D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, de Censi A.	An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.	Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. PMID: 25224760	2735
175	DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.	Breast Cancer Res Treat. 2014 Nov;148(1):81-90. PMID: 25253174	4198
174	Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E.	Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis taking into account Biases and Confounders.	Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. PMID: 24985407	5269



173	Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.	Ann Oncol. 2014 Jul;25(7):1373-8. PMID: 24728035	6578
172	Smith T, Elwood P, Keating C, Rothwell P, Detering E, Freedman A, Langley R, Logan R, Phillips C, DeCensi A.	The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.	Ecancermedicalsecience. 2014 Jan 24;8:388. PMID: 24678343	N/A
171	Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S.	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.	Breast Cancer Res Treat. 2014 Apr;144(2):321-9. PMID: 24487691	4198
170	Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P.	Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.	Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1862-7 PMID: 23945199	4.559
169	Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A.	Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.	Breast Cancer Res Treat. 2013 Dec;142(3):569-78. PMID: 24241787	4469
168	Gandini S, Guerrieri-Gonzaga A, Pruneri G,	Association of molecular subtypes with	Ann Oncol. 2014 Mar;25(3):618-23.	6578

	Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A.	Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.	PMID: 24351403	
167	Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B.	The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer.	Br J Cancer. 2013 Nov 26;109(11):2792-7 PMID: 24157825	5082
166	Lazzeroni M, DeCensi A.	Breast cancer prevention by antihormones and other drugs: where do we stand?	Hematol Oncol Clin North Am. 2013 Aug;27(4):657-72 PMID: 23915737	2.084
165	DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C, Muraca M, Segnan N,	Italian HOT Study Group. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.	AnnOncol. 2013 Nov;24(11):2753-60. PMID: 23864098	7384
164	Garassino MC, Martelli O, Broggin M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	Lancet Oncol. 2013 Sep;14(10):981-8. PMID: 23883922	25117
163	Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.	J Clin Oncol. 2013 Aug 10;31(23):2942-62 PMID: 23835710	18038
162	Serrano D, Lazzeroni M,	A randomized phase II		5872

	Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri MT, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, Decensi A, Bonanni B.	presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.	Breast Cancer Res. 2013 Jun 20;15(3):R47. PMID: 23786776	
161	Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, Lacroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; for the SERM Chemoprevention of Breast Cancer Overview Group.	Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.	Lancet. 2013 May 25;381(9880):1827-34. PMID: 23639488	39060
160	Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Castillo AD, Bassi F, Pagani G, Decensi A, Viale G, Bonanni B, Pruneri G.	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.	Br J Cancer. 2013 Apr 30;108(8):1593-601. PMID: 23535509	5082
159	Dunn BK, Cazzaniga M, Decensi A.	Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.	Breast. 2013 Jun;22(3):225-37. PMID:23535509	1967
158	Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, Decensi A.	Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.	Ann Oncol. 2013 Jul;24(7):1859-66. PMID: 23532115	7384
157	Puntoni M, Decensi A.	Allopurinol in subjects with colorectal adenoma--response.	Cancer Prev Res (Phila). 2013 Apr;6(4):369. PMID: 23447561	3.985
156	Gandini S, Guerrieri-	Metformin and breast	J Clin Oncol. 2013 Mar	18038

	Gonzaga A, Puntoni M, Decensi A.	cancer risk.	1;31(7):973-4. PMID: 23358989	
155	Puntoni M, Branchi D, Argusti A, Zanardi S, Crosta C, Meroni E, Munizzi F, Michetti P, Coccia G, De Roberto G, Bandelloni R, Turbino L, Minetti E, Mori M, Salvi S, Boccardo S, Gatteschi B, Benelli R, Sonzogni A, DeCensi A.	A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma.	Cancer Prev Res (Phila). 2013 Feb;6(2):74-81. PMID: 23213070	4891
154	Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A.	Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.	Breast Cancer Res. 2012 Oct 29;14(5):214. PMID: 23106852	5245
153	Bonelli L, Puntoni M, Gatteschi B, Massa P, Missale G, Munizzi F, Turbino L, Villanacci V, De Censi A, Bruzzi P.	Antioxidant supplement and long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized Trial.	J Gastroenterol. 2013 Jun;48(6):698-705. PMID: 23065023	3788
152	Defferrari C, Campora S, D'Amico M, Piccardo A, Biscaldi E, Rosselli D, Pasa A, Puntoni M, Gozza A, Gennari A, Zanardi S, Lionetto R, Bandelloni M, Decensi A.	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.	J Ovarian Res. 2012 Jun 25;5(1):17. PMID: 22732001	2.571
151	Simonato A, Varca V, Gacci M, Gontero P, De Cobelli O, Maffezzini M, Salvioni R, Carini M, Decensi A, Mirone V, Carmignani G.	Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study.	Adv Urol. 2012;2012:651061. Epub 2012 May 15. PMID: 22666241	N/A
150	Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG.	Exemestane for breast cancer prevention: a critical shift?	Cancer Discov. 2012 Jan;2(1):25-40 PMID: 22585166	10143
149	Bonanni B, Puntoni M, Cazzaniga M, Pruneri G,	Dual Effect of Metformin on Breast Cancer	J Clin Oncol. 2012 Jul 20;30(21):2593-600	24.008

	Serrano D, Guerrieri-Gonzaga A, Gennari A, Stella Trabacca M, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.	Proliferation in a Randomized Presurgical Trial.	PMID: 22564993	
148	Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.	Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.	Breast Cancer Res Treat. 2012 Jul;134(2):693-700. PMID:22562123	4431
147	Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.	Lancet Oncol. 2012 Apr;13(4):420-32.. PMID: 22265698	22589
146	Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A, Gargiulo S, Mastracci L, Nasti S, Palmieri G, Papadia F, Pastorino L, Russo A, Savarino V, Varesco L, Bernard L, Bianchi Scarrà G; Genoa Pancreatic Cancer Study Group	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy	Fam Cancer. 2012 Mar;11(1):41-7 PMID: 21989927	1302
145	Gennari A, Piccardo A, Altrinetti V, Corradengo D, Villavecchia G, De Censi A.	Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.	Curr Oncol Rep. 2012 Feb;14(1):20-6. PMID: 22094933	2545
144	Lazzeroni M, Gandini S, Puntoni M, Bonanni B, Gennari A, DeCensi A.	The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it	Breast. 2011 Oct;20 Suppl 3:S36-41 PMID: 22015291	2.089
143	Macis D, Gandini S, Guerrieri-Gonzaga A,	Prognostic effect of circulating adiponectin in a	J Clin Oncol. 2012 Jan 10;30(2):151-7.	18372

	Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.	randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.	PMID: 22162577	
142	Piccardo A, Altrinetti V, Bacigalupo L, Puntoni M, Biscaldi E, Gozza A, Cabria M, Iacozzi M, Pasa A, Morbelli S, Villavecchia G, Decensi A	Detection of metastatic bone lesions in breast cancer patients: Fused (18)F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience.	Eur J Radiol. 2012 Oct;81(10):2632-8. PMID: 22227259	2.606
141	Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, Bonelli L, Borgonovo G, Bruno W, De Cian F, Decensi A, Filauro M, Faravelli F, Gozza A, Gargiulo S, Mariette F, Nasti S, Pastorino L, Queirolo P, Savarino V, Varesco L, Scarrà GB; Genoa Pancreatic Cancer Study Group	CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.	J Med Genet. 2012 Mar;49(3):164-70 PMID: 22368299	6365
140	Rizzoli R, Body JJ, Decensi A, Reginster JY, Piscitelli P, Brandi ML; on behalf of the European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO)	Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Erratum in De Censi, A [corrected to DeCensi, A].	Osteoporos Int. 2012 Nov;23(11):2577 PMID: 22270857	4580
139	Decensi A, Pruneri G, Guerrieri-Gonzaga A.	Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?	J Clin Oncol. 2012 Apr 20;30(12):1384-6. PMID: 22393083	18372
138	Bruno S, Ghiotto F, Tenca C, Mazzarello AN, Bono M, Luzzi P, Casciaro S, Recchia A, Decensi A, Morabito F, Fais F	N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic	Leukemia. 2012 Oct;26(10):2260-8. doi: 10.1038/leu.2012.98. Epub 2012 Apr 5. PMID: 22475870.	9561

		leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.		
137	Maisonneuve P, Bagnardi V,  Bellomi M, Spaggiari L, Pelosi G, Rampinelli C, Field JK, Decensi A, Veronesi G	Lung cancer risk prediction to select smokers for screening CT - A model COSMOS trial.	Cancer Prev Res (Phila). 2011  Nov;4(11):1778-89. PMID: 21813406	4978
136	Montironi R, Bartels PH, Decensi A, Puntoni M, Hurler R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, Alberts DS, Maffezzini M.	A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry	Urol Oncol. 2013 Jul;31(5):557-65. Epub 2011 Jul 23. PMID: 21783387	N/A
135	Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G,  Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A, Viale G.	Immunohistochemistry by means of widely agreed- upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.	J Thorac Oncol. 2011 Jun;6(6):1039-49. PMID: 21512408	4040
134	Andrea DeCensi, Matteo  Puntoni, Giancarlo Pruneri, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Davide Serrano, Debora Macis, Harriet Johansson, Oriana Pala, Alberto Luini, Paolo Veronesi, Viviana Galimberti, Maria Cristina Dotti, Giuseppe Viale and	Lapatinib Activity in  Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo- Controlled Presurgical Trial.	Cancer Prev Res (Phila). 2011  Aug;4(8):1181-9. PMID: 21685235	4978
133	Bernardo Bonanni Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D,	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic	J Clin Oncol. 2011 Jun 1;29(16):2144-9. PMID: 21464403	18970

	Wilcken N, D'Amico M, Decensi A, Bruzzi P.	Review and Meta-Analysis of Randomized Clinical Trials		
132	Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H.	Preventive therapy for breast cancer: a consensus statement.	Lancet Oncol. 2011 May;12(5):496-503. Review. PMID: 21441069	33.9
131	Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B.	Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.	Cancer Prev Res (Phila). 2011 Jan;4(1):34-42. PMID: 21163939	4978
130	Decensi A, Gennari A.	Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care	J Clin Oncol. 2011 Jan 1;29(1):7-10. PMID: 21115871	18970
129	Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S.	Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.	Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61 PMID: 20947488	6000
128	Decensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B.	Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.	Ann Oncol. 2011 Mar;22(3):582-7. PMID: 20716629	6452
127	Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.	Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial	Pharmacogenomics J. 2011 Apr;11(2):100-7. PMID: 20309015	4306
126	Macis D, Cazzaniga M, Decensi A, Bonanni B.	Role of traditional and new biomarkers in breast carcinogenesis.	Ecancermedicalsecience. 2009;3:157. Epub 2009 Oct 29. PMID: 22276018	N/A
125	Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM)	Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey	Tumori. 2009 Nov-Dec;95(6):647-51. PMID: 20210223	0,791



124	Haugan Moi LL, Hauglid Flågå M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, De Censi A, Mellgren G.	Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue	Clin Cancer Res. 2010 Apr 1;16(7):2176-86. Erratum in: Clin Cancer Res. 2010 Oct 15;16(20):5087 PMID: 20332317	6747
123	Sogno I, Venè R, Ferrari N, De Censi A, Imperatori A, Noonan DM, Tosetti F, Albini A.	Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies.	Crit Rev Oncol Hematol. 2010 Jul;75(1):2-14. PMID: 20034809	4689
122	Morasso G, Di Leo S, Caruso A, Decensi A, Beccaro M, Berretta L, Bongiorno L, Cosimelli M, Finelli S, Rondanina G, Santoni W, Stigliano V, Costantini M.	Evaluation of a screening programme for psychological distress in cancer survivors.	Support Care Cancer. 2009 Nov 18. PMID: 20034809	2422
121	Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.	Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.	Clin Cancer Res. 2009 Nov 15;15(22):7053-60. PMID: 19887477	6488
120	Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.	Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.	Ann Oncol. 2009 Oct 25 PMID: 19858087	4935
119	Puntoni M, Decensi A.	The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.	Eur J Cancer. 2009 Sep;45 Suppl 1:346-54. Review. PMID: 19775631	4475
118	Andrea Decensi, Chris Robertson, Aliana Guerrieri-Gonzaga, Davide Serrano, Massimiliano Cazzaniga, Serena Mora, Marcella Gulisano, Harriet Johansson, Viviana Galimberti, Enrico Cassano, Simona Moroni, Franca Formelli, Ernst Lien, Giuseppe Pelosi, Karen J	Randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women	J Clin Oncol. 2009 Aug 10;27(23):3749-56. Epub 2009 Jul 13. PMID:19597031	17157
117	Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M,	Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single	Oncologist. 2009 Mar;14(3):201-12. PMID: 19264824	6630

	Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.	institution over 1x years		
116	Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O.	Biomarkers for risk assessment and prevention of breast cancer	Curr Cancer Drug Targets. 2009 Jun;9(4):482-99. PMID: 19519317	4316
115	Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A	Is it time to test metformin in breast cancer clinical trials?	Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5 PMID: 19240238	4770
114	Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, Campodonico F, Turbino L, Branchi D, Montironi R, Decensi A	Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies	Cancer Prev Res (Phila Pa). 2009 Apr;2(4):377-84 PMID: 19336728	N/A
113	Puntoni M, Bonanni B, Decensi A	Dietary changes after breast cancer in women without hot flashes: a simple and inexpensive way to target tumor and host?	J Clin Oncol. 2009 Jan 20;27(3):323-5 PMID: 19075255	17157
112	Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A	Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer	Cancer Res. 2008 Nov 15;68(22):9512-8 PMID: 19010927	7672
111	Puntoni M, Marra D, Zanardi S, Decensi A	Inflammation and Cancer Prevention	Ann Oncol 2008 Sep;19 Suppl 7:vii225-9. Review PMID: 18790956	4875
110	Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M	Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis	Breast Cancer Res Treat. 2009 Apr;114(3):599-605 PMID:18465220	5684
109	Rondanina G, Puntoni M, Severi G, Varricchio C, Zumino A, Feroce I, Bonanni B, Decensi A	Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users	J Clin Oncol, Vol 26, No 9 (March 20), 2008:1537-43 PMID:18349406	15484
108	Lazzeroni M, Macis D, Decensi A, Gandini S,	The effect of transdermal	Ecancermedalscience. 2008;2:67.	N/A

	Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B.	estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.	PMID: 22275964	
107	Serrano D, Gandini S, Mariani L, Bonanni B, Santinelli A, guerrieri-Gonzaga A, Pelosi G, Cassano E, Montironi R, Decensi A.	Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users	Breast 2008 Feb; 17(1):91-7 • PMID: 17768053	N/A
106	Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B.	A randomized dose-ranging trial of Tamoxifen at low doses in hormone replacement therapy users.	J Clin Oncol 2007 Sep 20;25(27):4201-9. PMID: 17709798	13598
105	Puntoni M, Zanardi S, Branchi D, Bruno S, Curotto A, Varaldo M, Bruzzi P, Decensi A.	Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.	Cancer Epidemiol Biomarkers Prev 2007 May;16(5):979-83. PMID: 17507625	4.289
104	Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D' Aiuto G, Oliviero P, Lovison F, Gucciardo G, Rosselli del Turco M, Muraca M.G, Pizzichetta M.A, Conforti S, Decensi A, The Italian Tamoxifen Study G	Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Trial Among Women with Hysterectomy	J Natl Cancer Inst 2007 May 2;99(9):727-37. PMID:17470740	15.271
103	Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A	Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women	Breast Cancer Res Treat. 2008 Mar;108(1):57-67. doi: 10.1007/s10549-007-9577-9. Epub 2007 Apr 28. PMID: 17468953.	4453

102	Decensi A.	Tamoxifen: an enduring star	J Natl Cancer Inst 2007 Feb 21;99(4):258-60  PMID: 17312297	12.271
101	Macis D, Maisonneuve P, Johansson H, Bonanni B, B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A.	Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta analysis.	Breast Cancer Res Treat. 2007 Dec;106(2):263-71.  PMID:17260091	4671
100	Decensi A, Zanardi S, Argusti A, Bonanni B, Costa A, Veronesi U.	Fenretinide and risk reduction of second breast cancer.	Nat Clin Pract Oncol. 2007 Feb;4(2):64-5. PMID:17259924	5364
99	Colombo N, Formelli F, Cantu MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A.	A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.	Cancer Epidemiol Biomarkers Prev 2006 Oct;15(10):1914-9. PMID:17035399	4460
98	Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU.	Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.	J Clin Oncol 2006 Aug 1;24(22):3708-9; author reply 3709. PMID:16877740	11810
97	M. Cazzaniga, G. Severi, C. Casadio, L. Chiapparini, U. Veronesi and A. Decensi.	Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer. .	Cancer Epidemiol Biomarkers Prev 2006 Jul; 15(7): 1311-5. PMID:16835329	4.460
96	U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, and G. De Palo.	Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer	Ann Oncol 2006 Jul; 17(7): 1065-71. epub 2006 May 4. PMID:16675486	4319.
95	Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A.	Clinical trials with retinoids for breast cancer chemoprevention	Endocr-Relat Cancer 2006 Mar; (13): 51-68. PMID:16601279	4905

94	Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A and Bonanni B.	Quality of life assessment in a chemoprevention trial fenretinide and HRT.	Maturitas 2006 Aug 20;55 (1) 69-75. Epub 2006 Feb 24 PMID:16500052	3.255
93	Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A.	Preliminary results of a randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.	J Clin Oncol 2006 Jan 1; 24(1):129-135.  PMID: 16382122	11810
92	Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A.	Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal 5 women with primary breast cancer.	Breast Cancer Res Treat 2006 Jul; 98 (2) : 167-72. PMID:16538534	4643
91	Gasco M, Argusti A, Bonanni B, Decensi A.	SERMs in chemoprevention of breast cancer.	Eur J Cancer 2005 Sep;41(13):1980-9. PMID: 15964182	6.029
90	Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U.	Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 54x8 women enrolled in Italian tamoxifen chemoprevention trial.	BMJ 2005 Apr 23;330(7497):932 PMID: 15746106	7038
89	Serrano D, Baglietto L, Johansson H, Mariette F, Torrisi R, Onetto M, Paganuzzi M, Decensi A.	Effect of the synthetic retinoid fenretinide on circulating free prostate specific antigen, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.	Clin Cancer Res 2005 Mar 1;11(5):2083-8 PMID:15756035	5623
88	Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D' Aiuto G,	Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.	Circulation 2005 Feb 8;111(5):650-6 PMID: 15699284	12563

	Gulisano M, Gucciardo G, Rosselli del Turco M, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U for the Italian Tamoxifen Study			
87	Serrano D, Lazzeroni M, Decensi A.	Chemoprevention of colorectal cancer: an Update.	Tech Coloproctol. 2004 Dec;8 Suppl 2:s248-52. Review. PMID:15666100	N/A
86	Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D, Serrano D, Sandri MT, Decensi A.	Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 74x women at risk for breast cancer.	Breast Cancer Res Treat 2004 Nov;88(1):63-73 PMID:15538047	2964
85	Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U.	A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.	Clin Cancer Res 2004 Jul 1;10(13):4389-97 PMID: 15240527	6511
84	Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA.	Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.	Clin Cancer Res 2004 Apr 1;10(7):2336-43 PMID: 15073109	6511
83	Serrano D, Perego E, Costa A, Decensi A.	Progress in chemoprevention of breast cancer.	Crit Rev Oncol Hematol 2004 Feb;49(2):109-17 PMID: 15012972	2979
82	Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri M.T, Mariette F, Lien E.A. And Decensi A.	Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women	J Thromb Haemost, 2003 1: 2149-2152 PMID: 14521597	N/A
81	Serrano D, Bonanni B, Cazzaniga M, Galli A, Gonzaga AG, Decensi A.	Pharmacological prevention of breast cancer: quo vadis?	Breast 2003 Dec;12(6):379-86 PMID: 14659109	0,481
80	Decensi A, Serrano D, Bonanni B, Cazzaniga M,	Breast cancer prevention trials using retinoids.	J Mammary Gland Biol Neoplasia 2003 Jan;8(1):19-30	2871

	Guerrieri-Gonzaga A.		PMID: 14587861	
79	Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F.	Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.	Clin Cancer Res 2003 Oct 15;9(13):4722-9 PMID: 14581342	5991
78	Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F.	Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.	Clin Cancer Res 2003 Jun;9(6):2032-9 PMID: 12796365	5991
77	Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrioni R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U	A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.	J Natl Cancer Inst. 2003 Jun 4;95(11):779-90. doi: 10.1093/jnci/95.11.779. PMID: 12783932	14500
76	Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group.	Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.	J Natl Cancer Inst 2003 Jan 15;95(2):160-5 PMID: 12529349	14500
75	Decensi A, Galli A, Veronesi U.	HRT opposed to low-dose tamoxifen (HOT study): rationale and design.	Recent Results Cancer Res. 2003;163:104-11; discussion 264-6. Review. PMID:12903847	N/A
74	Rotmensz N, Decensi A, Maisonneuve P, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Robertson C, Boyle P, Veronesi U.	Rationale for a study adding tamoxifen to HRT.	Eur J Cancer 2002 Nov;38 Suppl 6:S22-3 PMID: 12409061	3460
73	Decensi A.	[Risks and benefits of hormone replacement therapy: clinical considerations and research implications].	Epidemiol Prev. 2002 Nov-Dec;26(6):280-2. Italian PMID: 12619491	N/A

72	Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.	Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.	Circulation 2002 Sep 3;106(10):1224-8 PMID: 12208797	10517
71	De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U.	Effect of fenretinide on ovarian carcinoma occurrence.	Gynecol Oncol 2002 Jul;86(1):24-7 PMID: 12079295	2200
70	Guerrieri-Gonzaga A, Galli A, Rotmensz N, Decensi A.	The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives.	Ann N Y Acad Sci 2001 Dec;949:113-22 PMID: 11795343	1381
69	Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrissi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA, Decensi A.	Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women.	Breast Cancer Res Treat 2001 Sep;69(1):21-7 PMID: 11759825	2720
68	Torrissi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A.	Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.	Br J Cancer 2001 Dec 14;85(12):1838-41 PMID:11747323	3489
67	Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F.	Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.	Cancer Epidemiol Biomarkers Prev 2001 Oct;10(10):1047-53 PMID:11588130	4354
66	Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT, Canigiula L, Lampreda C, Diani S, Lien EA, Decensi A.	Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.	Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):967-70 PMID:11535549	4354
65	Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME,	Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled,	Cancer Epidemiol Biomarkers Prev 2001 Sep;10(9):961-6 PMID:11535548	4354



	Scott T, Muchmore DB.	randomized clinical trial in postmenopausal patients.		
64	Torrise R, Decensi A, Formelli F, Camerini T, De Palo G.	Chemoprevention of breast cancer with fenretinide.	Drugs 2001;61(7):909-18. Review. PMID:11434448	3966
63	Bonanni B, Guerrieri-Gonzaga A, Rotmensch N, Torrisi R, Pigatto F, Cazzaniga M, Mora S, Diani S, Robertson C, Decensi A.	Hormonal Therapy and Chemoprevention.	Breast J. 2000 Oct;6(5):317-323. PMID: 11348390.	N/A
62	Veronesi U, Decensi A.	Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials.	J Natl Cancer Inst 2001 Apr 4;93(7):486-8 PMID: 11287432	14159
61	Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U.	Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.	J Clin Oncol 2001 Mar 15;19(6):1664-70 PMID: 11250995	24.008
60	Torrise R, Decensi A.	Fenretinide and cancer prevention.	Curr Oncol Rep. 2000 May;2(3):263-70. Review. PMID: 11122852.	N/A
59	Baglietto L, Torrisi R, Arena G, Tosetti F, Gonzaga AG, Pasquetti W, Robertson C, Decensi A.	Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.	Cancer Detect Prev 2000;24(4):369-75 PMID: 11059568	0,927
58	Decensi A, Bonanni B, Rotmensch N, Robertson C, Guerrieri-Gonzaga A, Mora S, Diani S, Cazzaniga M, Costa A.	Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study.	Eur J Cancer 2000 Sep;36 Suppl 4:S50-1 PMID: 11056317	2537
57	Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolo G, Malcangi B, Gatteschi B, Rondanina G ...	Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.	Cancer Epidemiol Biomarkers Prev 2000 Oct;9(10):1071-8 PMID: 11045790	3572
56	Torrise R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A.	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer	Int J Cancer 2000 Aug 15;87(4):601-5 PMID:10918204	3545

		chemoprevention trial.		
55	Decensi A, Costa A.	Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.	Eur J Cancer 2000 Apr;36(6):694-709 PMID: 10762741	2537
54	Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrissi R, Manetti L, Robertson C, De Palo G, Formelli F, Costa A, Veronesi U.	Chemoprevention of breast cancer: the Italian experience.	J Cell Biochem Suppl 2000;34:84-96 PMID:10762020	N/A
53	Veronesi U, De Palo G, Marubini E, Costa A,  Mariani L, Formelli F, Decensi A.	Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?	J Natl Cancer Inst 2000 Feb 2;92(3):274; author reply 274-5 PMID: 10655447	12.945
52	Bruno S, Torrissi R, Costantini M, Baglietto L, Fontana V, Gatteschi B, Melioli G, Nicolo G, Curotto A, Malcangi B, Bruttini GP, Varaldo M, Bruzzi P, Decensi A.	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.	J Cell Biochem 1999 Dec;76(2):311-21 PMID: 10618647	2778
51	Decensi A, Gandini S, Guerrieri-Gonzaga A,  Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA.	Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.	J Clin Oncol 1999 Sep;17(9):2633-8  PMID:10561336	8228
50	Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB.	Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.	J Natl Cancer Inst 1999 Nov 3;91(21):1847-56 PMID: 10547391	10730
49	Decensi A, Robertson C, Ballardini B, Paggi D, Guerrieri-Gonzaga A,  Bonanni B, Manetti L, Johansson H, Barreca A, Bettega D, Costa A.	Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.	Eur J Cancer 1999 Apr;35(4):596-600 PMID:10492633	2743
48	Decensi A, Torrissi R, Gozza	Effect of fenretinide on	Breast Cancer Res Treat 1999	2287

	A, Severi G, Bertelli G, L, Traverso A, Milone S, Dini D, Costa A	bone mineral density and metabolism in women with early breast cancer.	Jan;53(2):145-51 PMID: 10326791	
47	Decensi A, Torrisci R, Fontana V, Barreca A, Ponzani P, Pensa F, Parodi S, Costa A.	Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial.	Eur J Cancer 1998 Jun;34(7):999-1003 PMID:9849446	2407
46	Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U.	Biologic activity of tamoxifen at low doses in healthy women.	J Natl Cancer Inst 1998 Oct 7;90(19):1461-7 PMID: 9776411	11403
45	Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costa A, Veronesi U.	Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.	Br J Cancer 1998 Sep;78(5):572-8 PMID: 9744493	2938
44	Fontana V, Decensi A, Orenge MA, Parodi S, Torrisci R, Puntoni R.	Socioeconomic status and survival of gastric cancer patients.	Eur J Cancer 1998 Mar;34(4):537-42 PMID: 9713305	6.029
43	Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, Mannucci PM, Decensi A.	Tamoxifen reduces plasma homocysteine levels in healthy women.	Br J Cancer 1998 Jun;77(12):2264-6 PMID: 9649143	2938
42	Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A, Decensi A.	Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.	Br J Cancer 1998 Jun;77(12):2138-47 PMID: 9649125	2938
41	Torrisci R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A.	Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.	Int J Cancer 1998 Jun 10;76(6):787-90 PMID: 9626341	3362
40	Costa A, Bonanni B, Manetti L, Guerrieri Gonzaga A, Torrisci R, Decensi A.	Prevention of breast cancer: focus on chemoprevention.	Recent Results Cancer Res. 1998;152:11-21. PMID: 9928543	N/A
39	De Palo G, Camerini T, Marubini E, Costa A,	Chemoprevention trial of contralateral breast cancer	Tumori 1997 Nov-Dec;83(6):884-94	N/A

	Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U.	with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.	PMID: 9526578	
38	Decensi A, Fontana V, Fioretto M, Rondanina G, Torrisi R, Orengo MA, Costa A.	Long-term effects of fenretinide on retinal function.	Eur J Cancer 1997 Jan;33(1):80-4 PMID: 9071904	N/A
37	Decensi A, Costa A.	Polyprenolic acid in hepatocellular carcinoma.	N Engl J Med 1996 Nov 7;335(19):1461; author reply 1461-2 PMID: 8927082	N/A
36	Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A.	Effect of tamoxifen on endometrial proliferation.	J Clin Oncol 1996 Feb;14(2):434-40 PMID: 8636754	N/A
35	Veronesi U, De Palo G, Costa A, Formelli F, Decensi A.	Chemoprevention of breast cancer with fenretinide.	IARC Sci Publ. 1996; (136):87-94. Review. PMID: 8791119	N/A
34	Bruno S, Machi AM, Semino C, Meta M, Ponte M, Varaldo M, Curotto A, Ferlazzo G, Decensi A, Melioli G.	Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer.	Cancer Immunol Immunother 1996 Jan;42(1):47-54 PMID: 8625366	N/A
33	Costa A, De Palo G, Decensi A, Formelli F, Chiesa F, Nava M, Camerini T, Marubini E, Veronesi U.	Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.	Ann N Y Acad Sci 1995 Sep 30;768:148-62 PMID: 8526344	N/A
32	Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG.	Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.	Cancer Res 1995 Feb 15;55(4):853-61 PMID: 7850799	N/A
31	Torrisi R, Pensa F, Fontana V, Costa A, Decensi A.	The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.	Eur J Cancer 1995;31A(3):420-1 PMID: 7786612	N/A
30	Torrisi R, Parodi S, Fontana	Factors affecting plasma	Cancer Epidemiol	N/A

	V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A.	retinol decline during long- term administration of the synthetic retinoid fenretinide in breast cancer patients.	Biomarkers Prev 1994 Sep;3(6):507-10  PMID: 8000302	
29	Decensi A, Curotto A, Bruno S, Costantini M, Torrasi R, Gatteschi B, Cussotto M, Pizzorno R, Quattrini S, Repetto U, Schenone M, Tentarelli T, Bruzzi P.	DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.	Eur J Cancer Prev 1994 Jul;3(4):377- 9 PMID: 7950899	N/A
28	Costa A, Formelli F, Chiesa F, Decensi A, De Palo G,  Veronesi U.	Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.	Cancer Res 1994 Apr 1;54(7 Suppl):2032s-2037s  PMID: 8137334	N/A
27	Decensi A, Torrasi R, Fontana V.	Stimulation of erythropoiesis by the non- steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?	Br J Cancer 1994 Mar;69(3):617-9 PMID: 8123500	N/A
26	Decensi AU, Formelli F, Torrasi R, et al.	Fenretinide in breast cancer chemoprevention (review).	Oncology Rep 1: 817-24, 1994. PMID: 21607448	N/A
25	Decensi A, Bruno S, Costantini M, Torrasi R, Curotto A, Gatteschi B,  Nicolo G, Polizzi A, Perloff	Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an	J Natl Cancer Inst 1994 Jan 19;86(2):138-40 PMID: 8271297	N/A
24	M, Malone WF. Decensi A, Torrasi R, Polizzi A, Gesi R, Brezzo V,  Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A.	intermediate end point. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.	J Natl Cancer Inst 1994 Jan 19;86(2):105-10.  PMID: 8271292	N/A
23	Decensi A, Torrasi R, Marroni P, Pensa F,  Padovani P, Boccardo F.	Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.	Prostate 1994;24(1):17-23 PMID:8290386	N/A
22	Boccardo F, Cannata D,  Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F,	Prophylaxis of superficial  bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.	J Clin Oncol 1994 Jan;12(1):7- 13 PMID: 8270987	N/A

	Salvia G, Comeri G, Bono A, Borella T, Giuliani L.			
21	Decensi A, Bruno S, Torrisci R, Parodi S, Polizzi A.	Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.	Eur J Cancer 1994;30A(12):1909-10 PMID: 7880629	N/A
20	Torrisci R, Pensa F, Orenco MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A.	The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.	Cancer Res 1993 Oct 15;53(20):4769-71 PMID: 8402658	N/A
19	Decensi A, Torrisci R, Fontana V, Marroni P, Padovani P, Guarneri D, Minuto F, Boccardo F.	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer.	Acta Endocrinol (Copenh) 1993 Oct;129(4):315-21 PMID: 8237249	N/A
18	Costa A, Sacchini V, Decensi A.	Retinoids and tamoxifen in breast cancer chemoprevention.	Int J Clin Lab Res 1993;23(2):53-5 PMID: 8518414	N/A
17	Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M, Delliponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G.	Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.	Eur J Cancer 1993;29A(8):1088-93 PMID: 8518017	N/A
16	Decensi A, Formelli F, Torrisci R, Costa A.	Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.	J Cell Biochem Suppl 1993;17G:226-33 PMID: 8007703	N/A
15	Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F.	Carboplatin in advanced hormone refractory prostatic cancer patients.	Eur J Cancer 1993;29A(15):2094-6 PMID: 7507687	N/A
14	Boccardo F, Guarneri D, Pace M, Decensi A, Oneto F, Martorana G.	Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients.	Tumori 1992 Apr 30;78(2):137-9 PMID: 1523706	N/A
13	Decensi A, Bruno S, Giaretti W, Torrisci R, Curotto A, Gatteschi B, Geido E, Polizzi	Activity of 4-HPR in superficial bladder cancer using DNA flow	J Cell Biochem Suppl 1992;16I:139-47 PMID:1305678	N/A

	A, Costantini M, Bruzzi P, Nicolò G, Costa A, Boccardo F, Giuliani L, Santi L.	cytometry as an intermediate endpoint.		
12	Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L.	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.	J Urol 1991 Aug;146(2):377-81 PMID:1856935	N/A
11	Decensi A, Guarneri D, Paoletti MC, Lalanne JM, Merlo F, Boccardo F.	Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).	Eur J Cancer 1991;27(9):1100-4 PMID:1835617	N/A
10	Canobbio L, Boccardo F, Guarneri D, Calabria C, Decensi A, Curotto A, Martorana G, Giuliani L.	Phase II study of navelbine in advanced renal cell carcinoma.	Eur J Cancer 1991;27(6):804-5 PMID:1829928	N/A
9	Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Mini E, Macaluso MP, Giuliani L, Santi L, Periti P.	Anandron (RU 239x8) in metastatic prostate cancer: preliminary results of a multicentric Italian study.	Cancer Detect Prev 1991;15(6):501-3 PMID: 1782640	N/A
8	Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F.	Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.	J Cancer Res Clin Oncol 1990;116(5):503-6 PMID: 2229142	N/A
7	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G.	Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).	Eur Urol 1990;18 Suppl 3:48-53 PMID: 2151277	N/A
6	Decensi AU, Guarneri D, Marroni P, Di Cristina L, Paganuzzi M, Boccardo F.	Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men.	J Urol 1989 Nov;142(5):1235-8 PMID:2530360	N/A
5	Boccardo F, Decensi A, Guarneri D, Martorana G, Giberti C, Giuliani L.	Estramustine phosphate (estracyt) following androgens in men with refractory stage D2	Cancer Chemother Pharmacol 1988;22(2):172-4 PMID: 3409448	N/A

		prostate cancer.		
4	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Martorana G, Giberti C, Cerruti GB, Tani F, Zanollo A, Germinale T, Borzone C, Perri F, Usai E, Santi L, Giuliani L.	Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial.	Am J Clin Oncol 1988;11 Suppl 2:S129-31 PMID:3409448	N/A
3	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Massa T, Martorana G, Giberti C, Cerruti GB, Tani F, Zanollo A, Germinale T, Borzone C, Perri F, Usai E, santi L, Giuliani L.	Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.C.A.P.) study.	Prostate 1987;11(3):243-55 PMID: 2960957	N/A
2	Robustelli della Cuna G, Zanon P, Pavesi L, Preti P, Prada GA, Decensi A.	An overview of clinical trials with high-dose medroxyprogesterone acetate. (HD-MPA) in endocrine-related tumors other than breast cancer.	Chemioterapia 1986 Jun;5(3):164-72 PMID:2941173	N/A
1	Decensi A, Guarneri D, Boccardo F.	[Medullary carcinoma of the thyroid. Natural history, diagnosis and therapy].	Minerva Med. 1986 Nov 17;77(44):2131-5. Italian. PMID: 2878394	N/A

Publications retrieved from bibliographic sources other than PubMed

N	Authors	Title	Publication and source link	IF
12	Roberta Rapetti, Barbara Fiorini, Matteo Puntoni, Andrea DeCensi, Giuliano Lo Pinto	The nurse-physician collaboration: a survey among Internal Medical Units in Liguria region	Italian Journal of Medicine Vol 8, No 4 (2014) <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653902">https://www.scopus.com/authid/detail.uri?authorId=7006653902</a>	N/A
11	Lazzeroni, M., Petrera, M., Marra, D., Decensi, A.	Aspirin and breast cancer prevention	Current Breast Cancer Reports Sep2013, Vol 5, Issue 3, 202–207 <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a>	N/A
10	Francesco Sardanelli, Franca Podo, Giuliano D'Agnolo,	Multicenter comparative	Radiology 2007. 242(3), 698-715.	5251



	<p>Arduino Verdecchia, Mariano Santaquilani, Renato Musumeci, Giovanna Trecate, Siranoush Manoukian, Sandro Morassut, Clelia de Giacomi, Massimo Federico, Laura Cortesi, Stefano Corcione, Stefano Cirillo, Vincenzo Marra, Anna Cilotti, Cosimo Di Maggio, Alfonso Fausto, Lorenzo Preda, Chiara Zuiani &amp; 82 others</p>	<p>multimodality surveillance of women at genetic- familial high risk for breast cancer (HIBCRIT Study): Interim results</p>	<p><a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a> 902</p>	
9	<p>Heckman-Stoddard, B. M., Lee, O., Lazzeroni, M., Khan, S., DeCensi, A., &amp; Dunn, B. K.</p>	<p>Innovative approaches to tamoxifen administration for breast cancer prevention.</p>	<p>In Tamoxifen Concepts and Cancer: New Paradigms (pp. 61-86). Nova Science Publishers, Inc., (2012) <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a> 902</p>	N/A
8	<p>Costa, A., Serrano, D., Ballardini, B., Decensi, A.</p>	<p>The current status of chemoprevention of breast cancer</p>	<p>2004 CME Journal of Gynecologic Oncology <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a> 902</p>	N/A
7	<p>Veronesi U, Maisonneuve P, Rotmensz N, Decensi A, Viale G, Boyle P.</p>	<p>Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High- Risk Women.</p>	<p>J Natl Cancer Inst 2003 June 18; 95 (12): 918-919 <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a> 902</p>	14500
6	<p>Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri Gonzaga A, Ramazzotti F, Johansson H,</p>	<p>Re: Effect of transdermal estradiol and oral conjugated estrogen on c- reactive protein in retinoid</p>	<p>Circulation 2003 May;107:e127-e128 (reply). <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653">https://www.scopus.com/authid/detail.uri?authorId=7006653</a></p>	10255

	Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.	placebo trial in healthy women.	authorId=7006653 902	
5	Hole, D., Stallard, S., Holli, K., Decensi, A.,  Jakesz, R.	Hormones and breast cancer	2002 Breast  <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653902">https://www.scopus.com/authid/detail.uri?authorId=7006653902</a>	0,5
4	Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N,  Boyle P; Italian Tamoxifen Study Group (citato tra i membri).	Tamoxifen for breast cancer among  hysterectomised women.	Lancet 2002 Mar 30;359(9312):1122-4 <a href="http://www.sciencedirect.com/science/article/pii/S014067360208159X?via%3Dihub">http://www.sciencedirect.com/science/article/pii/S014067360208159X?via%3Dihub</a>	13251
3	Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C,  Rotmensz N, Boyle P.	Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study (citato tra i membri).	Lancet 1998 Jul 11;352(9122):93-7	16135
2	Sheinfeld, J., Herr, H.W., Boone, C.W., De Censi AU, Reuter, V., Soloway, M.S.	Intervention strategies for  chemoprevention of bladder cancer	1992 Journal of Cellular  Biochemistry  <a href="https://www.scopus.com/authid/detail.uri?authorId=7006653902">https://www.scopus.com/authid/detail.uri?authorId=7006653902</a>	N/A
1	Decensi AU, Guarneri D, Boccardo F	Nafarelin acetate and benign prostatic hyperplasia.	N Engl J Med. 1988 Mar 3;318(9):580-1. <a href="https://jhu.pure.elsevier.com/en/publications/nafarelin-acetate-and-benign-prostatic-hyperplasia-3">https://jhu.pure.elsevier.com/en/publications/nafarelin-acetate-and-benign-prostatic-hyperplasia-3</a>	N/A

Dr. Andrea De Censi



Jan 15, 2021

